Takeda Pharmaceutical
303 hedge funds and large institutions have $953M invested in Takeda Pharmaceutical in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 100 increasing their positions, 93 reducing their positions, and 43 closing their positions.
4,520% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $496K
8% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 93
0% more funds holding
Funds holding: 302 → 303 (+1)
0.13% less ownership
Funds ownership: 2.4% → 2.27% (-0.13%)
19% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 43
35% less capital inflows, than outflows
Capital inflows: $110M | Capital outflows: $170M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$21.8M |
| 2 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$9.34M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$7.01M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$6.83M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mondrian Investment Partners
London,
United Kingdom
|
-$70M |
| 2 |
Millennium Management
New York
|
-$19.3M |
| 3 |
Causeway Capital Management
Los Angeles,
California
|
-$10.4M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.33M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$6.33M |
TAK Hedge Fund Activity: Q4 2024 in Review
303 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2024, worth a combined $953M — down 6.1% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of TAK and 35 opened new positions — a net loss of 8 holders — while 93 trimmed existing stakes and 100 added.
The largest buyer was UBS Group, adding an estimated $21.8M. The largest seller was Mondrian Investment Partners, cutting an estimated $70M.
- 303 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2024, up from 302 in Q3 2024.
- Funds reported $953M of Takeda Pharmaceutical stock for Q4 2024, down 6.1% quarter-over-quarter.
- 35 funds opened new Takeda Pharmaceutical positions in Q4 2024 and 43 closed out, a net change of -8 holders.
- The largest Takeda Pharmaceutical buyer in Q4 2024 was UBS Group, an estimated $21.8M added.
- The largest Takeda Pharmaceutical seller in Q4 2024 was Mondrian Investment Partners, an estimated $70M sold.
Based on aggregated 13F filings for Q4 2024.